Pfizer Says REFLECTIONS B7391003 Study Met Primary Objective - Quick Facts

Pfizer Inc. (PFE) said that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin (bevacizumab), met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin.

from RTT - Biotech http://ift.tt/2uso43m
via IFTTT